Company / Working Capital
Oruka Therapeutics, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$13.0M
FY2024
5-year range
-$13.0M / $50.9M
FY2020-FY2024
Trend
-135.3%
vs FY2023
Sector context
#209 of 213
Health Care
What the data says
Among 213 Health Care companies, Oruka Therapeutics, Inc. is in the bottom 2% for working capital. Working Capital has declined for 3 consecutive years, from $51M in FY2021 to -$13M in FY2024.
Based on SEC 10-K filings.
-$13M in FY2024.
Declined from $42M to -$13M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 213This company -$13.0M Sector average $934.6M
▼
-101.4% below sector average
Key checks
Key Insights
- Oruka Therapeutics, Inc.'s working capital has declined for 3 consecutive years.
- In FY2024, working capital decreased 135.3% year-over-year.
- Ranks #209 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$13.0M | -135.3% |
| FY2023 | $37.0M | -11.1% |
| FY2022 | $41.6M | -18.4% |
| FY2021 | $50.9M | +9.6% |
| FY2020 | $46.5M | +515.2% |
| FY2019 | $7.6M | +26.2% |
| FY2018 | $6.0M | -41.5% |
| FY2017 | $10.2M | -46.3% |
| FY2016 | $19.0M | -49.1% |
| FY2015 | $37.4M | +165.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026